Abstract
A few studies have looked at the efficacy of tofacitinib in severe alopecia areata (AA), characterized by ≥ 50% scalp hair loss. Here, we aimed to assess retrospective data for the role of tofacitinib as an induction agent in severe AA, compared with the standard oral mini-pulse (OMP). Tofacitinib holds promise as an induction agent for patients with severe AA, comparable with OMP. However, when patients respond inadequately to tofacitinib, a trial of pulse steroids may be considered.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
